JP2020518613A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518613A5
JP2020518613A5 JP2019560156A JP2019560156A JP2020518613A5 JP 2020518613 A5 JP2020518613 A5 JP 2020518613A5 JP 2019560156 A JP2019560156 A JP 2019560156A JP 2019560156 A JP2019560156 A JP 2019560156A JP 2020518613 A5 JP2020518613 A5 JP 2020518613A5
Authority
JP
Japan
Prior art keywords
lamp
improved lamp
lamp construct
antigen
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019560156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518613A (ja
JP7222915B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030725 external-priority patent/WO2018204534A1/en
Publication of JP2020518613A publication Critical patent/JP2020518613A/ja
Publication of JP2020518613A5 publication Critical patent/JP2020518613A5/ja
Priority to JP2022209238A priority Critical patent/JP7407902B2/ja
Application granted granted Critical
Publication of JP7222915B2 publication Critical patent/JP7222915B2/ja
Priority to JP2023213451A priority patent/JP7657282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019560156A 2017-05-02 2018-05-02 癌抗原を含む改善されたｌａｍｐ構築物 Active JP7222915B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022209238A JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたｌａｍｐ構築物
JP2023213451A JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたｌａｍｐ構築物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762500053P 2017-05-02 2017-05-02
US62/500,053 2017-05-02
US201762561760P 2017-09-22 2017-09-22
US62/561,760 2017-09-22
PCT/US2018/030725 WO2018204534A1 (en) 2017-05-02 2018-05-02 Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209238A Division JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたｌａｍｐ構築物

Publications (3)

Publication Number Publication Date
JP2020518613A JP2020518613A (ja) 2020-06-25
JP2020518613A5 true JP2020518613A5 (enExample) 2021-05-27
JP7222915B2 JP7222915B2 (ja) 2023-02-15

Family

ID=62528827

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019560156A Active JP7222915B2 (ja) 2017-05-02 2018-05-02 癌抗原を含む改善されたｌａｍｐ構築物
JP2022209238A Active JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたｌａｍｐ構築物
JP2023213451A Active JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたｌａｍｐ構築物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022209238A Active JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたｌａｍｐ構築物
JP2023213451A Active JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたｌａｍｐ構築物

Country Status (10)

Country Link
US (2) US12358962B2 (enExample)
EP (1) EP3618854A1 (enExample)
JP (3) JP7222915B2 (enExample)
KR (2) KR20200016224A (enExample)
CN (1) CN110913892A (enExample)
AU (1) AU2018263923B9 (enExample)
BR (1) BR112019023014A2 (enExample)
CA (1) CA3061950A1 (enExample)
IL (2) IL270271B2 (enExample)
WO (1) WO2018204534A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100004A1 (en) * 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
AU2020366515A1 (en) * 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
EP4082560B1 (en) * 2021-04-27 2025-02-26 Academia Sinica Prap1 polypeptide for use in treating hypertriglyceridemia
EP4508071A1 (en) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4397844A (en) 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
GB2026340B (en) 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4681762A (en) 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4592002A (en) 1983-12-13 1986-05-27 Honeywell Inc. Method of digital temperature compensation and a digital data handling system utilizing the same
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
AU665758B2 (en) 1991-04-26 1996-01-18 Surface Active Limited Novel antibodies, and methods for their use
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
KR970000862B1 (ko) 1992-06-09 1997-01-20 호프 아크티엔게젤샤프트 래치 및 잠금장치
GB9213033D0 (en) 1992-06-19 1992-08-05 British Telecomm Method of controlling a telecommunications network
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
CA2161684C (en) 1994-03-07 2010-11-09 Larry R. Wilson Bioactive and/or targeted dendrimer conjugates
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
AU2946295A (en) 1994-06-27 1996-01-19 Johns Hopkins University, The Targeted gene delivery system
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DK1323346T3 (da) 1995-01-17 2006-10-30 Brigham & Womens Hospital Receptorspecifik transport af immunogener gennem epitelet
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
EP0920339A2 (en) 1996-07-09 1999-06-09 The Johns Hopkins University Gene delivery system
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
DE69739961D1 (de) 1996-12-13 2010-09-23 Schering Corp Methoden zur Virus-Reinigung
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
EP0989849A2 (en) 1997-06-13 2000-04-05 The Johns Hopkins University School Of Medicine Therapeutic nanospheres
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
DK1199368T3 (da) 1998-07-07 2004-04-13 Transgene Sa Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
US6511832B1 (en) 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
US8318173B2 (en) 2001-04-05 2012-11-27 The John Hopkins University Chimeric vaccines
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
US20070269457A1 (en) 2006-05-16 2007-11-22 The Buck Institute For Age Research Immunotherapeutic compositions and methods
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
WO2011031298A1 (en) 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
WO2011046996A2 (en) 2009-10-13 2011-04-21 The Johns Hopkins University Consensus sequence for influenza a virus
EP2697256A1 (en) * 2011-04-15 2014-02-19 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
US20160185831A1 (en) 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
BR112016030439A2 (pt) 2014-06-23 2018-07-17 Immunomic Therapeutics Inc ácidos nucléicos para o tratamento de alergias ao amendoim.
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
BR112019022108A2 (pt) * 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. Construções de lamp aprimoradas

Similar Documents

Publication Publication Date Title
US12162909B2 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
JP2020518613A5 (enExample)
ES2675825T3 (es) Vacunación tumoral que involucra una respuesta inmunitaria contra la proteína propia CLDN18.2
JP2017523789A5 (enExample)
JP6519929B2 (ja) Ｇｌｐ−１類似体融合タンパク質とその作製方法及び用途
JP2015509707A5 (enExample)
RU2016145061A (ru) Профилактическая вакцина против синдрома падения яйценоскости (eds)
JP2020532287A (ja) 癌の治療のためのネオアンチゲンワクチン組成物
JP2019013229A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
WO2018232353A4 (en) Bacterial vaccine
US20160122420A1 (en) Antibody display
CN101031647B (zh) 在大肠杆菌中制备猪丹毒杆菌表面保护性抗原变体的方法
CN106279435A (zh) 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina
JP2015156814A (ja) アカバネウイルスに対して中和活性を有する抗体を誘導するペプチド
CN117384298A (zh) 一种快速规模化生产病毒样颗粒疫苗或药物的方法
US11459364B2 (en) Calbindin and BH3 domain chimeric proteins and methods for use
Xu et al. Fusion of parathyroid hormone (1–34) to an albumin-binding domain improves osteogenesis
US12121574B2 (en) Malaria immunogen and methods for using same
JP2017500030A5 (enExample)
Drew et al. The human IgG3 hinge mediates the formation of antigen dimers that enhance humoral immune responses to DNA immunisation
JPWO2022187424A5 (enExample)
US20240166696A1 (en) Scaffolds For Inducing Antibody Responses Against Antigenic Sites
US10525127B2 (en) P14.7 protein and uses thereof as vaccine adjuvant
JPWO2020188081A5 (enExample)